Market news

GlucoTrack subsidiary Lokahi Therapeutics secured its first external fee-for-service partnership with nonprofit Innovate GBM for glioblastoma research.

Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to $3.99. The

GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.

GlucoTrack shares soar 80% after-hours as Lokahi Therapeutics signs first external glioblastoma licensing partnership with Innovate GBM.

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines (NASDAQ:GRML) shares

RUTHERFORD, N.J. & LA JOLLA, Calif., September 23, 2026--Lōkahi CEO Erik Emerson outlines LT-100 progress, ai² platform growth, and a strategy to discover, advance, and monetize assets.

Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.

RUTHERFORD, N.J. & LA JOLLA, Calif., September 11, 2026--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth.

Tipranks Press Release.

Tipranks Press Release.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 27, 2026--Glucotrack (Nasdaq: GCTK) announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 25, 2026--Lōkahi Therapeutics™ initiates GMP manufacturing of LT-100 and advances preparations for the program's next clinical milestone.

Glucotrack (NASDAQ:GCTK) has regained compliance with Nasdaq’s stockholders’ equity requirement, with the Nasdaq Hearings Panel granting the company’s request for continued listing subject to certain conditions. The Nasdaq compliance milestone removes one specific listing issue for Glucotrack as management continues its strategic transformation, although the company said it is still working toward full compliance with all applicable Nasdaq standards.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 17, 2026--"We are approaching the months ahead with confidence, urgency, and a clear sense of purpose," said Erik Emerson, CEO of Glucotrack.

Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 05, 2026--Glucotrack, Inc. (NASDAQ: GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors, including a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in the form of convertible debt.

Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.

Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap stands at

Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding shares is at $1.8

GlucoTrack shares surged 70.25% after hours as investors reacted to its simplified single-injection strategy for LT-100 development.

RUTHERFORD, N.J. & LA JOLLA, Calif., July 29, 2026--Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company disc

Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.

GlucoTrack shares jumped 15.98% after-hours as investors reacted to Lokahi Therapeutics merger news and restructuring plans.

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor in the strategic business combination between Glucotrack, Inc. (Nasdaq: GCTK) and Lōkahi Therapeutics, and as exclusive placement agent for a concurrent convertible note financing of approximately $5.7 million to support the combined company's post-closing growth. The transaction establishes a public

RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (

Glucotrack has completed its business combination with Lōkahi Therapeutics, transforming the company into a Lōkahi-controlled public platform focused on acquiring and advancing healthcare assets while retaining its continuous blood glucose monitoring business as a standalone subsidiary. Key Investor TakeawaysGlucotrack (NASDAQ:GCTK) completed its strategic business combination with Lōkahi Therapeutics.

By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.